Get the app Watchlists Portfolios Alerts Sign in Get started

Menu

Synthetic Biologics, Inc. SYN

Full chart Compare

Set alert

1.02 +1.02

Day range unavailable

52-week range unavailable

News

1 day ago globenewswire.com Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. – Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – –…